GIM
ACAD icon

Glenmede Investment Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Glenmede Investment Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,669
Closed -$57.6K – 1415
2025
Q2 		$57.6K Buy
+2,669
New +$49.6K ﹤0.01% 1360

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Glenmede Investment Management's ACAD Position: Q3 2025 in Review

Glenmede Investment Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2025, closing a stake of 2,669 shares — an estimated $57.6K sold.

Glenmede Investment Management first reported a position in ACAD in Q2 2025 and held it in 1 quarter. The position peaked at $57.6K in Q2 2025. 333 funds tracked by Wall St. Rank hold ACAD as of Q3 2025.

  • Glenmede Investment Management reported no remaining Acadia Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Glenmede Investment Management sold 2,669 Acadia Pharmaceuticals shares in Q3 2025, an estimated $57.6K.
  • Glenmede Investment Management first reported a position in Acadia Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Glenmede Investment Management's Acadia Pharmaceuticals position peaked at $57.6K in Q2 2025.
  • 333 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.